Artesunate - Frantz Viral Therapeutics

Drug Profile

Artesunate - Frantz Viral Therapeutics

Latest Information Update: 11 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Georgetown University
  • Developer Frantz Viral Therapeutics
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia

Most Recent Events

  • 11 May 2017 Chemical structure information added
  • 20 Apr 2017 Phase-I clinical trials in Anal intraepithelial neoplasia in USA (Rectal) (NCT03100045)
  • 10 Apr 2017 Georgetown University has patent protection for the use of artemisinins for the treatment of HPV-induced cervical dysplasia/cancer, anal cancer and head and neck cancer in Europe, and far East
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top